Company intelligence / Profile preview

Quentis Therapeutics

New York, New York, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Quentis Therapeutics has developed first-in-class small molecule inhibitors targeting IRE1α to modulate ER stress responses in the tumor microenvironment. The company’s lead candidate was expected to enter clinical trials around or after 2019. No published clinical results are available; all programs remain preclinical as per latest public data.

Therapeutic areas: OncologyOther
Modalities: Small moleculesPotentially monoclonal antibodies (patents mention mAbs)
Industry: Biotech

Beyond the preview

Go deeper on Quentis Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quentis Therapeutics.

Explore the full profile